JulietEWolfordMD

Gynecologic Oncology

Gynecologic Oncologist

Dr. Wolford is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
3700 Southern Blvd
Ste 201
Kettering, OH 45429
Phone+1 855-500-2873

Fax+1 937-281-3992

University of California (Irvine)Fellowship, Gynecologic Oncology, 2016 - 2020
University of California (Irvine)Residency, Obstetrics and Gynecology, 2012 - 2016
Marshall University Joan C. Edwards School of MedicineClass of 2012

PubMed

22 citations
Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.
Juliet E Wolford, Jiaru Bai, Kathleen N. Moore, Rebecca Kristeleit, Bradley J. Monk
Gynecologic Oncology. 2020-05-01
14 citations
A profile on the FoundationFocus CDxBRCA tests
Lindsey Ford, Juliet E Wolford, Sandra Brown, Leslie M. Randall
Expert Review of Molecular Diagnostics. 2020-02-06
4 citations
Integrating Precision Medicine into the Contemporary Management of Gynecologic Cancers.
Juliet E Wolford, Erin Ferrigni, Daniel Margul, Thomas J Herzog
Current Oncology Reports. 2022-07-01

Journal Articles

Cost-Effectiveness of Niraparib, Rucaparib, and Olaparib for Treatment of Platinum-Resistant, Recurrent Ovarian Carcinoma
Juliet Wolford, MD, Gynecologic Oncology

Lectures

SOLO1 versus SOLO2: Cost-effectiveness of olaparib as maintenance therapy for newly diagnosed and platinum-sensitive recurrent ovarian carcinoma among women with germl...
ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019

OncLive® Announces Winners of the 2019 Innovative Technology in Cancer Care ChallengeNovember 12th, 2019